D
David H. Collier
Researcher at Amgen
Publications - 89
Citations - 8221
David H. Collier is an academic researcher from Amgen. The author has contributed to research in topics: Etanercept & Rheumatoid arthritis. The author has an hindex of 27, co-authored 89 publications receiving 6979 citations. Previous affiliations of David H. Collier include University of Colorado Boulder & National Health Service.
Papers
More filters
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Bashar Kahaleh,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
Philip J. Clements,Daniel E. Furst,Weng Kee Wong,Maureen D. Mayes,Barbara White,Fredrick M. Wigley,Michael H. Weisman,Walter G. Barr,Larry W. Moreland,Thomas A. Medsger,Virginia D. Steen,Richard J. Martin,David H. Collier,Arthur Weinstein,Edward V. Lally,John Varga,Steven R. Weiner,Brian S. Andrews,Micha Abeles,James R. Seibold +19 more
TL;DR: This study cannot answer the question of whether low-dose D-Pen is effective, but it does suggest that there is no advantage to using D- penicillamine in doses higher than 125 every other day.
Journal ArticleDOI
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
Peter A. Merkel,Peter A. Merkel,Karen Herlyn,Richard J. Martin,Jennifer J. Anderson,Maureen D. Mayes,Patrice Bell,Joseph H. Korn,Robert W. Simms,Mary Ellen Csuka,Thomas A. Medsger,Naomi F. Rothfield,Michael H. Ellman,David H. Collier,Arthur Weinstein,Daniel E. Furst,Sergio A. Jimenez,Barbara White,Barbara White,James R. Seibold,Fredrick M. Wigley +20 more
TL;DR: It is demonstrated that the significant activity, disability, pain, and psychological impact of RP and digital ulcers in SSc can be measured by a small set of valid and reliable outcome measures.
Journal ArticleDOI
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
James R. Seibold,Joseph H. Korn,Robert W. Simms,P. J. Clements,Larry W. Moreland,Maureen D. Mayes,Daniel E. Furst,Naomi F. Rothfield,Virginia D. Steen,Michael H. Weisman,David H. Collier,Fredrick M. Wigley,Peter A. Merkel,Mary Ellen Csuka,Vivien Hsu,Susan Rocco,Mark Erikson,John F. Hannigan,W. Scott Harkonen,Martin E. Sanders +19 more
TL;DR: In this paper, the efficacy, safety, and dose-response effect of recombinant human relaxin in patients with scleroderma was evaluated in a randomized, double-blind, placebo-controlled trial.